CA2652421A1 — Treatment for depressive disorders
Assigned to Vanda Pharmaceuticals Inc · Expires 2007-11-29 · 18y expired
What this patent protects
A method for treating a depressive disorder is provided which comprises administering a melatonin agonist alone, or in combination wit additional antidepressant medication(s). The depressive disorder treated is one or more of major depression, dysthymia or bipolar disorder. A kit…
USPTO Abstract
A method for treating a depressive disorder is provided which comprises administering a melatonin agonist alone, or in combination wit additional antidepressant medication(s). The depressive disorder treated is one or more of major depression, dysthymia or bipolar disorder. A kit is also provided comprising one or more pharmaceutical dose units of a melatonin agonist and one or more pharmaceutical dose units of an antidepressant. The individual dose.units may each further comprise an antidepressant or antipsychotic, and optionally one or more pharmaceutically active ingredients.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.